Aadi Bioscience, Inc. (AADI) 은(는) 상장 기업입니다 헬스케어 섹터의 바이오 산업에서 운영. 본사 소재지는 Pacific Palisades, CA, 미국. 현재 CEO는 David J. Lennon.
AADI 을(를) 보유 IPO 날짜 2018-02-16, 53 명의 정규직 직원, 에 상장 NASDAQ Capital Marke, 시가총액 $94.89M.
Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.
